Back to Search
Start Over
Progress in treating migraines: promising prospects for a better tomorrow.
- Source :
- Bulletin of the National Research Centre; 8/21/2023, Vol. 47 Issue 1, p1-4, 4p
- Publication Year :
- 2023
-
Abstract
- Background: Migraine is a debilitating disorder that undoubtedly has a significant impact both clinically and socially. New treatment options are necessary in Iran due to issues with tolerance, interactions, contraindications, and the lack of effectiveness of current medications. Main text and a short conclusion: Gepants are small compounds that target calcitonin gene-related peptide and are currently in further clinical development as preventive treatment alternatives for migraine. However, their development was halted due to hepatotoxicity, so this process still needs to be completed. Recent clinical trials have demonstrated the effectiveness, safety, and general patient tolerability of the latest generation of gepants. In light of this information, we aim to provide readers with a concise and helpful overview of the two types of gepants and their potential side effects. [ABSTRACT FROM AUTHOR]
- Subjects :
- SUMATRIPTAN
CALCITONIN gene-related peptide
MIGRAINE
Subjects
Details
- Language :
- English
- ISSN :
- 25228307
- Volume :
- 47
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Bulletin of the National Research Centre
- Publication Type :
- Academic Journal
- Accession number :
- 170040240
- Full Text :
- https://doi.org/10.1186/s42269-023-01105-x